The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir plus cobicistat plus emtricitabine plus tenofovir combination therapy for the treatment of HIV

被引：7
作者：
Raffe, Sonia [1 ]
Fisher, Martin [1 ]
机构：
[1] Royal Sussex Cty Hosp, Brighton BN2 5BE, E Sussex, England
来源：
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2015年 / 11卷 / 03期
关键词：
cobicistat; elvitegravir; HIV; Stribild; NON-INFERIORITY TRIAL; REGIMEN ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DF; CO-FORMULATED ELVITEGRAVIR; INITIAL TREATMENT; DOUBLE-BLIND; INFECTION ANALYSIS; COFORMULATED ELVITEGRAVIR; DISOPROXIL FUMARATE; OPEN-LABEL; IN-VITRO;
D O I：
10.1517/17425255.2015.997207
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Introduction: Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir (EVG/COBI/FTC/TDF or Stribild (TM)) is the latest antiretroviral tablet approved in the EU. This review aims to provide an overview of its role in the management of HIV-1 infection. Areas covered: This review covers material searched and obtained through Medline and Pubmed up to July 2014. Expert opinion: Antiretroviral treatment prevents the progressive destruction of the immune system by the HIV, significantly reducing morbidity and mortality. The efficacy and tolerability of EVG/COBI/FTC/TDF compared to current standard of care as a single-tablet treatment choice has been shown in study 102 and study 103. Its use is restricted to patients without significant pre-existing renal impairment and may be limited by concomitant medications but undoubtedly increases treatment choice for HIV-1-infected adults.
引用
收藏
页码：427 / 435
页数：9
相关论文
共 24 条
[1]  
[Anonymous], 2014, Summary of Product Characteristics - VIREAD, P1
[2]   Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial [J].
Arribas, Jose R. ;
Pialoux, Gilles ;
Gathe, Joseph ;
Di Perri, Giovanni ;
Reynes, Jacques ;
Tebas, Pablo ;
Thai Nguyen ;
Ebrahimi, Ramin ;
White, Kirsten ;
Piontkowsky, David .
LANCET INFECTIOUS DISEASES, 2014, 14 (07) :581-589
[3]  
British HIV Association Writing Group, 2012, BHIVA GUID TREATM HI, P1
[4]   Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results [J].
Clumeck, Nathan ;
Molina, Jean-Michel ;
Henry, Keith ;
Gathe, Joseph ;
Rockstroh, Juergen K. ;
DeJesus, Edwin ;
Wei, Xuelian ;
White, Kirsten ;
Fordyce, Marshall W. ;
Rhee, Martin S. ;
Szwarcberg, Javier .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) :E121-E124
[5]  
Custodio JM, 2013, MOPE036 7 IAS C KUAL
[6]   Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients [J].
DeJesus, Edwin ;
Berger, Daniel ;
Markowitz, Martin ;
Cohen, Calvin ;
Hawkins, Trevor ;
Ruane, Peter ;
Elion, Richard ;
Farthing, Charles ;
Zhong, Lijie ;
Cheng, Andrew K. ;
McColl, Dainian ;
Kearney, Brian P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :1-5
[7]   Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial [J].
DeJesus, Edwin ;
Rockstroh, Juergen K. ;
Henry, Keith ;
Molina, Jean-Michel ;
Gathe, Joseph ;
Ramanathan, Srinivasan ;
Wei, Xuelian ;
Yale, Kitty ;
Szwarcberg, Javier ;
White, Kirsten ;
Cheng, Andrew K. ;
Kearney, Brian P. .
LANCET, 2012, 379 (9835) :2429-2438
[8]  
European Environment Agency, 2014, GUID QUAL OR MOD REL, P1
[9]   Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function [J].
German, Polina ;
Liu, Hui C. ;
Szwarcberg, Javier ;
Hepner, Mischa ;
Andrews, Jessica ;
Kearney, Brian P. ;
Mathias, Anita .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (01) :32-40
[10]   Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV [J].
German, Polina ;
Warren, David ;
West, Steve ;
Hui, James ;
Kearney, Brian P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (03) :323-329
123